PDX Model Cohort
Biliary Tract Cancer PDX Models
An advanced cohort of well-characterized Biliary Tract Cancer - Gallbladder & Cholangiocarcinoma PDX models directly established from late-stage primary and metastatic tumors available for drug development research.
Summary
Biliary tract cancers (BTCs) pose considerable therapeutic challenges due to their aggressive progression and limited treatment options. To advance research and drug development, Champions has established a distinctive cohort of 20* patient-derived xenograft (PDX) models, representing gallbladder cancer and cholangiocarcinoma PDX models. These clinically relevant models are derived from patients with advanced, metastatic BTCs who have undergone multiple lines of treatment, including chemotherapy, targeted therapy, and immunotherapy, while preserving key molecular characteristics and driver mutations.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' premier biliary tract models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to a robust bank of biliary tract cancer - Gallbladder & Cholangiocarcinoma PDX models with clinically relevant molecular and pathological characteristics.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Includes models pretreated with advanced therapies like Cisplatin, Epirubicin, Capecitabine, and more.